Alembic Pharma reports net profit of Rs 176 crores in Q3FY22

Alembic Pharma has reported its consolidated financial results for the quarter ending 31st December, 2021. The net profit of the company stands at Rs 176 crores for this quarter with net sales at Rs 1,272 crores. The net sales for the nine-month period (FY22) is at Rs 3,890 crores with net profit during the same period at Rs 510 crores, Alembic Pharma notified in a statement.

Shaunak Amin, Managing Director, Alembic Pharma, said in the statement, “India branded business has posted a strong growth rate for the third consecutive quarter. Strong operational performance is attributed to consistent efforts of team and strengthening of customer relationships. Branded business witnessed market outperforming growth across most of the key products and therapy areas.”

Apart from it, the statement notified that the US generics stood at Rs 393 crores in the quarter and at Rs 1,109 crores for 9M FY22. Ex-US international formulations stood at Rs 193 crores in the quarter and at Rs 587 crores for 9M FY22. Further, there were six ANDA filings during the quarter; cumulative ANDA filings stood at 220. In addition, four ANDA approvals were received during the quarter, including two tentative; 154 cumulative ANDA approvals, including 20 tentative.

India branded business stood at Rs 488 crores in the quarter and at Rs 1,478 crores in the 9M FY22. Acute speciality segment grew faster than IPM. API business stood at Rs 198 crores in the quarter and at Rs 716 crores for 9M FY22, and one DMF was filed in the quarter, the statement concluded.